Revenue segments as reported by the company.

Grant revenue

Clinical trial revenue

Contract revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

General and administrative

Research and development

Selling and marketing

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Longeveron

Longeveron, Inc. is a clinical stage biotechnology company. It engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young, healthy, adult donors. The company was founded by Joshua M. Hare and Donald M. Soffers on October 9, 2014 and is headquartered in Miami, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Longeveron reports promising Q1 results, secures funding for growth

Longeveron's Q1 2024 earnings call highlighted positive Phase I results for HLHS and cost management efforts. The company secured funding for further development and welcomed new board members. Challenges include regulatory hurdles and market competition, but opportunities lie in expanding therapeutic applications and revenue growth potential.

Longeveron reports positive Q2 results, eyes contract services expansion

Longeveron's Q2 2024 earnings call highlighted strong performance in trials and financials, with a focus on HLHS program advancement and contract services expansion. The company faces challenges in addressing analyst inquiries and maximizing its contract services business potential, but has opportunities for revenue growth and leveraging positive trial outcomes.

Longeveron reports robust revenue growth and progresses towards FDA approval

Longeveron's Q3 2024 performance reflects strong revenue growth and advancements in regulatory pathways for their product candidate, Lomecel-B, across multiple therapeutic areas.
The company's focus on cellular therapies aligns with a lucrative market potential in the U.S., but funding needs for accelerated activities and competitive challenges pose considerations for future strategies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Longeveron, Inc. is a clinical stage biotechnology company, which engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young, healthy, adult donors. The company was founded by Joshua M. Hare and Donald M. Soffer on October 9, 2014 and is headquartered in Miami, FL.

Dr. Min will lead global clinical development and regulatory strategy Dr. Min will lead global clinical development and regulatory strategy

Longeveron Expands Executive Leadership Team; Appoints K. Chris Min, M.D.

Longeveron (LGVN) stock is taking off on Thursday after the drugmaker published news related to an Alzheimer's treatment. The post Alzheimer's News: Why Is Drugmaker Longeveron (LGVN) Soaring Today?

Alzheimer's News: Why Is Drugmaker Longeveron (LGVN) Soaring Today?

Longeveron Inc (NASDAQ: LGVN) shares are trading higher Thursday after the company announced the publication of results from a Phase 1 trial testing Lomecel-B on patients with mild Alzheimer's disease in "Alzheimer's & Dementia: The Journal of the Alzheimer's Association.

Why Longeveron Shares Are Surging Today

Results Support Further Exploration of Therapeutic Potential of Lomecel-B to Slow Cognitive Decline, Improve Quality of Life for Alzheimer's Patients

Longeveron Publishes Peer Reviewed Study of Phase 1 Trial Results of Lomecel-B for Alzheimer's Disease in Alzheimer's & Dementia®: The Journal of the Alzheimer's Association

Longeveron management presents live at the Second Euro-Geroscience Conference and at a pre-meeting task force Longeveron management presents live at the Second Euro-Geroscience Conference and at a pre-meeting task force

Longeveron Presents at Second Euro-Geroscience Conference

Argo Blockchain PLC

B. Riley Principal 150 Merger Corp

Enservco

Novavax

Energy is understandably at the top of every investor's mind right now, but finding the best energy stocks requires careful consideration. The post 5 Cheap Energy Stocks Riding Oil Higher appeared first on InvestorPlace.

5 Cheap Energy Stocks Riding Oil Higher

MIAMI, March 15, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today that Geoff Green, Chief Executive Officer at Longeveron, will present at the upcoming Oppenheimer 32nd Annual Healthcare Conference on Wednesday, March 16, 2022. Details of Longeveron's participation follow below:

Longeveron to Present at Oppenheimer 32nd Annual Healthcare Conference

Longeveron Inc. (LGVN) CEO Geoff Green on Q4 2021 Results - Earnings Call Transcript

Currently Enrolling Clinical Trials with Lomecel-B in Three Disease Indications: Hypoplastic Left Heart Syndrome (Phase 2a), Alzheimer's Disease (Phase 2a), and Covid-related Acute Respiratory Distress Syndrome (Phase 1)

Longeveron Announces Fourth Quarter and Full Year 2021 Financial Results and Operational Progress

Longeveron is rising before the release of its Q4 2021 earnings report. Here's what investors should know about LGVN stock and why.

Why Is Longeveron (LGVN) Stock Up Today?

Live Conference Call At 8:30 a.m. EST Live Conference Call At 8:30 a.m. EST

Longeveron to Announce Fourth Quarter and Full Year 2021 Financial Results, on March 11, 2022

MIAMI, March 02, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today that Geoff Green, Chief Executive Officer at Longeveron, will present at the upcoming Q1 Virtual Investor Summit on Tuesday, March 8, 2022. Details of Longeveron's participation follow below:

Longeveron to Present at Q1 Virtual Investor Summit Conference

Girolamo brings legal, finance and M&A experience to cell therapy company Girolamo brings legal, finance and M&A experience to cell therapy company

Longeveron Adds Seasoned Biotech Executive Todd Girolamo to Its Board of Directors

Tesla

Tema Electrification ETF

Insider trading can be highly revealing when looking for moonshot stocks to buy. Here's three with insiders buying worth looking at.

3 Moonshot Stocks For 2022

Longeveron obtained Rare Pediatric Designation of Lomecel-B for patients with hypoplastic left heart syndrome. All 10 patients who received Lomecel-B were alive and had not required a transplant between 2 to 3.5 years post-surgery.

Longeveron: Speculative Biotech Worth A Look On Rare Disease, Aging, And Alzheimer's Focuses

Greenwich Lifesciences

When insiders buy a stock, you should take it as a sign that they think good news is about to come out. Here are three to watch closely.

3 Stocks Insiders Are Buying on Market Turbulence

Longeveron management will present live in multiple sessions at the Advanced Therapies Week at the Miami Beach Convention Center Longeveron management will present live in multiple sessions at the Advanced Therapies Week at the Miami Beach Convention Center

Longeveron to Participate in Phacilitate Advanced Therapies Week

MIAMI, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and certain life-threatening conditions, announced today publication of the design and rationale from its recently completed Phase 2b aging frailty clinical trial with Lomecel-B in the Journal of Frailty and Aging . This peer-reviewed article describes the design of the trial which investigated Lomecel-B, a living cell therapy product, as a regenerative medicine strategy for the treatment of frailty in older adults.

Longeveron Announces Publication of Lomecel-B Phase 2b Trial Design in Journal of Frailty and Aging

Investors are reacting positively to the beginning of an Alzheimer's disease trial with Longeveron's lead candidate, Lomadel-B.

Here's Why Longeveron Stock Jumped Higher on Wednesday

AbbVie

Biogen

Bristol-Myers

Hoth Therapeutics

Johnson & Johnson

Pfizer

The Alzheimer's Disease treatment market is known for its vast potential given the fact that there are hardly any active drugs and therapies that produce any real improvements in patients' conditions.

These Emerging Biotechs Could Beat Alzheimer's Disease

Longeveron Inc (NASDAQ: LGVN) is trading higher Wednesday after the company announced initiation of the Phase 2a clinical trial of lomecel-B for the treatment of Alzheimer's disease. The trial is designed to measure brain anatomy using MRI, and include detailed assessments of the inflammatory and vascular systems thought to contribute to the worsening of Alzheimer's disease.

Why Longeveron Shares Are Rising Today

The stock price of Longeveron Inc (NASDAQ: LGVN) increased by over 17% pre-market today. This is why it happened.

Longeveron Stock (LGVN): Why The Price Surged Today

Trial designed to obtain safety and efficacy data of single and multiple dosing regimen Trial designed to obtain safety and efficacy data of single and multiple dosing regimen

Longeveron Announces Initiation of Phase 2a Clinical Trial of Lomecel-B for the Treatment of Alzheimer's Disease

Longeveron CEO Geoff Green to give presentation and will participate in panel discussion titled “The Emerging Cell & Gene Therapy Landscape—From Hope to Reality” moderated by Dr. Scott Gottlieb, former Commissioner of the FDA Longeveron CEO Geoff Green to give presentation and will participate in panel discussion titled “The Emerging Cell & Gene Therapy Landscape—From Hope to Reality” moderated by Dr. Scott Gottlieb, former Commissioner of the FDA

Longeveron to Participate in the H.C. Wainwright BioConnect 2022 Virtual Conference

iSpecimen

Petros Pharmaceuticals

Reliance Global Group

Vallon Pharmaceuticals

Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next huge movie. GameStop Corp (NYSE:GME) and AMC Entertainment Holdings (NYSE:AMC) are two high-profile examples of short squeezes earlier this year.

News for Longeveron Stock (LGVN)